Orchestrating the Tumor Microenvironment in Colorectal Cancer

Daniel Sur^{1, 2,} and Alexandru Irimie^{2, 3}

¹Department of Medical Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania

²Oncology Department, “Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania

³Department of Oncological Surgery and Gynecological Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Cite this paper:
Daniel Sur and Alexandru Irimie. Orchestrating the Tumor Microenvironment in Colorectal Cancer. International Journal of Celiac Disease. 2020; 8(3):107-109. doi: 10.12691/ijcd-8-3-7

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide. Despite the improvement of treatment options that bettered advanced-stage patient’s overall survival, the clinical outcome is still poor. The tumor microenvironment is thought to be an essential participant in the metastasis process. Liver metastases are the most frequent metastases that occur in CRC patients. It is believed that colorectal cancer has the liver as a preferential site for metastasis, and this is possible due to the multiple interactions that happen in the tumor microenvironment and due to the tumor stem cells input. As a means to investigate this biological process, microRNAs (miRNAs) have established a name for themselves as putative biomarkers in cancer and especially colorectal cancer. In this pilot study, we explored miRNAs expression that by influencing the tumor stem cells can help prevail liver metastasis in advanced-stage CRC patients.

Keywords:
colorectal cancer liver metastases tumor microenvironment tumor stem cells miRNA

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global patterns and trends in colorectal cancer incidence and mortality,” Gut, vol. 66, no. 4, pp. 683-691, 2017.
[2]	A. Bhalla, M. Zulfiqar, and M. H. Bluth, “Molecular Diagnostics in Colorectal Carcinoma,” Clin. Lab. Med., vol. 38, no. 2, pp. 311-342, 2018.
[3]	G. D. Lianos, G. K. Glantzounis, A. Mangano, S. Rausei, and D. H. Roukos, “Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: Can this be translated to patient benefit?,” Futur. Oncol., vol. 10, no. 10, pp. 1723-1726, 2014.
[4]	V. G. Peddareddigari, D. Wang, and R. N. Dubois, “The tumor microenvironment in colorectal carcinogenesis,” Cancer Microenviron., vol. 3, no. 1, pp. 149-166, 2010.
[5]	M. De Robertis, M. L. Poeta, E. Signori, and V. M. Fazio, “Current understanding and clinical utility of miRNAs regulation of colon cancer stem cells,” Semin. Cancer Biol., vol. 53, pp. 232-247, 2018.
[6]	J. Thomas, M. Ohtsuka, M. Pichler, and H. Ling, “MicroRNAs: Clinical relevance in colorectal cancer,” Int. J. Mol. Sci., vol. 16, no. 12, pp. 28063-28076, 2015.
[7]	S. K. Shenouda and S. K. Alahari, “MicroRNA function in cancer: Oncogene or a tumor suppressor?,” Cancer Metastasis Rev., vol. 28, no. 3-4, pp. 369-378, 2009.
[8]	M. Y. Shah, A. Ferrajoli, A. K. Sood, G. Lopez-Berestein, and G. A. Calin, “microRNA Therapeutics in Cancer- An Emerging Concept,” EBioMedicine, vol. 12, pp. 34-42, 2016.
[9]	M. J. Munro, S. K. Wickremesekera, L. Peng, S. T. Tan, and T. Itinteang, “Cancer stem cells in colorectal cancer: A review,” J. Clin. Pathol., vol. 71, no. 2, pp. 110-116, 2018.
[10]	R. D. M. Maria Lucia Ricci-Vitiani, Eros Fabrizi, Elisabetta Palio, “Colon cancer stem cells,” J Mol Med, vol. 87, pp. 1097-1104, 2009.
[11]	A. Drusco et al., “MicroRNA profiles discriminate among colon cancer metastasis,” PLoS One, vol. 9, no. 6, p. e96670, 2014.
[12]	O. Slaby, M. Svoboda, J. Michalek, and R. Vyzula, “MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application,” Mol. Cancer, vol. 8, pp. 1-13, 2009.
[13]	A. K. S. Rajesha Rupaimoole, George A. Calin, Gabriel Lopez-Berestein, “MicroRNA deregulation in cancer cells and the tumor microenvironment,” Cancer Discov, vol. 6, no. 3, pp. 235-246, 2016.
[14]	H. Chen and Z. Xu, “Hypermethylation-Associated Silencing of miR-125a and miR-125b: A Potential Marker in Colorectal Cancer,” Dis. Markers, vol. 2015, pp. 1-7, 2015.
[15]	Q. B. Wu et al., “MicroRNA-125 inhibits RKO colorectal cancer cell growth by targeting VEGF,” Int. J. Mol. Med., vol. 42, no. 1, pp. 665-673, 2018.
[16]	W. Dong-xu, L. Jia, and Z. Su-juan, “MicroRNA-185 is a novel tumor suppressor by negatively modulating the Wnt/β-catenin pathway in human colorectal cancer,” Indian J. Cancer, vol. 52, no. 7, p. 182, 2016.
[17]	Z. Zhang et al., “STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer,” Oncogene, vol. 34, no. 37, pp. 4808-4820, 2015.
[18]	B. Wang and Q. Zhang, “The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors,” J. Cancer Res. Clin. Oncol., vol. 138, no. 10, pp. 1659-1666, 2012.
[19]	V. Kulda et al., “Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases,” Cancer Genet. Cytogenet., vol. 200, no. 2, pp. 154-160, 2010.